Wungki Park
YOU?
Author Swipe
View article: Transcriptomic Plasticity is a Hallmark of Metastatic Pancreatic Cancer
Transcriptomic Plasticity is a Hallmark of Metastatic Pancreatic Cancer Open
Metastasis is the leading cause of cancer deaths. To develop strategies for intercepting metastatic progression, a better understanding of how tumor cells adapt to vastly different organ contexts is needed. To investigate this question, a …
View article: OR19-06 Safety and Effectiveness of Sulfonylureas for Pancreas-Cancer Induced Metabolic Dysregulation
OR19-06 Safety and Effectiveness of Sulfonylureas for Pancreas-Cancer Induced Metabolic Dysregulation Open
Disclosure: J.H. Flory: None. H. Martirosova: None. E. Tan: None. M. Bakkar: None. M. Goncalves: None. W. Park: None. E. O'Reilly: None. Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by new-onset diabetes with rapid …
View article: The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions
The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions Open
While the coding genome of pancreatic cancer has been characterized in detail, features of the noncoding genome remain relatively unexplored. We used whole-genome sequencing to study the coding and noncoding genomes (promoters, enhancers, …
View article: Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma
Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma Open
Background The influence of obesity and sex on outcomes in pancreatic adenocarcinoma (PDAC) remains unclear. The association between obesity (body mass index [BMI], ≥30) and biologic sex (male or female) for outcomes in patients with PDAC …
View article: Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial Open
The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib in 63 participants with metastatic pancreatic cancer with disease control on platinum-based chemotherapy. Participants were prospectively stratified into three cohor…
View article: Transcriptomic plasticity is a hallmark of metastatic pancreatic cancer
Transcriptomic plasticity is a hallmark of metastatic pancreatic cancer Open
Metastasis is the leading cause of cancer deaths; nonetheless, how tumor cells adapt to vastly different organ contexts is largely unknown. To investigate this question, we generated a transcriptomic atlas of primary tumor and diverse meta…
View article: RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer Open
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may solve this challenge …
View article: Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival Open
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic of disease out…
View article: <i>KRAS</i> Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers
<i>KRAS</i> Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers Open
PURPOSE KRAS variants are associated with poor outcomes in biliary tract cancers (BTCs). This study assesses the prevalence of KRAS variants and their association with survival and recurrence in patients with intrahepatic cholangiocarcinom…
View article: Automated real-world data integration improves cancer outcome prediction
Automated real-world data integration improves cancer outcome prediction Open
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text and si…
View article: Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort Open
Background Adjuvant modified leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) is standard of care for fit individuals with resected pancreatic ductal adenocarcinoma (PDAC). Data are limited on adjuva…
View article: EGFR-directed antibodies promote HER2 ADC internalization and efficacy
EGFR-directed antibodies promote HER2 ADC internalization and efficacy Open
Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody drug conjugate that has remarkable activity in HER2-positive cancers. However, the degree of benefit of T-DXd is not uniform among solid…
View article: Genomic evolution of pancreatic cancer at single-cell resolution
Genomic evolution of pancreatic cancer at single-cell resolution Open
We adapted a previously developed targeted single-nucleus DNA sequencing (snDNA-seq) method and constructed a new suite of computational analysis tools to study 137,491 single-nucleus DNA libraries from 24 pancreatic cancers collected unde…
View article: Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of <i>KRAS</i> G12C-mutated disease
Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of <i>KRAS</i> G12C-mutated disease Open
Background Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are obser…
View article: Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery
Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery Open
Introduction: The rate of isolated locoregional recurrence after surgery for pancreatic adenocarcinoma (PDAC) approaches 25%. Ablative radiation therapy (A-RT) has improved outcomes for locally advanced disease in the primary setting. We s…
View article: Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma
Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma Open
PURPOSE Intrahepatic cholangiocarcinoma (ICCA) is characterized by significant phenotypic and clinical heterogeneities and poor response to systemic therapy, potentially related to underlying heterogeneity in oncogenic alterations. We aime…
View article: Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma Open
PURPOSE To determine the genetic predisposition underlying pancreatic acinar cell carcinoma (PACC) and characterize its genomic features. METHODS Both somatic and germline analyses were performed using an Food and Drug Administration–autho…
View article: Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden Open
Background Pembrolizumab is FDA approved for tumors with tumor mutational burden (TMB) of ≥10 mutations/megabase (mut/Mb). However, the response to immune checkpoint inhibitors (ICI) varies significantly among cancer histologies. We descri…
View article: Pancreatic Cancer: BRCA Targeted Therapy and Beyond
Pancreatic Cancer: BRCA Targeted Therapy and Beyond Open
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related death in the US by 2030, despite accounting for only 5% of all cancer diagnoses. Germline gBRCA1/2-mutated PDAC represents a key subg…
View article: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoant…
View article: Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge
Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge Open
Poorly differentiated pancreatic neuroendocrine tumors (PDNEC), are a subtype of pancreatic cancer encompassing both small cell and large cell neuroendocrine carcinoma subtypes, and are characterized as distinct in terms of biology and pro…
View article: Supplementary Figure from Clinico-genomic Characterization of <i>ATM</i> and HRD in Pancreas Cancer: Application for Practice
Supplementary Figure from Clinico-genomic Characterization of <i>ATM</i> and HRD in Pancreas Cancer: Application for Practice Open
Supplementary Figure from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice